Skip to content

Advertisement

  • Poster presentation
  • Open Access

Association Between the Presence of CCR5-specific Antibodies and Long Term Non Progression

  • 1, 2Email author,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Retrovirology20052 (Suppl 1) :P130

https://doi.org/10.1186/1742-4690-2-S1-P130

  • Published:

Keywords

  • Infectious Disease
  • Cancer Research
  • Vaccine Design
  • Seronegative Donor
  • Uninfected Subject

Most transmitted HIV-1 strains use CCR5 as coreceptor. Antibodies (Abs) to CCR5 have been detected in highly exposed to HIV-1 but uninfected subjects, thus they could be involved in HIV protection. To assess whether these Abs may also contribute to slow HIV-disease progression, we searched for anti-CCR5 Abs in 499 subjects, including 87 Long Term Non Progressors (LTNP), 70 Progressors, 135 HIV+ HAART treated, and 207 seronegative donors. We found anti-CCR5 Abs in a fraction of LTNP (22.9%), but not in the other populations studied (p < 0.0001). These Abs efficiently prevent infection of HIV-R5 strains representing subtypes B, C and A by inducing a stable and long last down regulation of CCR5 on surface of T lymphocytes. Follow-up studies showed that the loss of anti-CCR5 Abs, occurred in some subjects, was significantly associated with a progression toward disease. Thus, the anti-CCR5 Abs could be relevant to vaccine design and therapeutics.

Notes

Authors’ Affiliations

(1)
Immunology and Infectious Disease Dep, San Raffaele Scientific Institute, Milano, Italy
(2)
Duke University Medical Center, SORF Bldg, Durham, NC, USA

Copyright

© The Author(s) 2005

Advertisement